Metraipolis › archive › dc_09360437d17f

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or… — Europe PMC PMID:41077611

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41077611
DOI
10.1038/s41392-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-11-09T09:08:47.539Z
SHA-256 of the archived text
223b9878a15f36640f6b443675bb3214c029693390e2237872ca7c2e306dbdee
Stable URL of this page
https://metraipolis.com/documento/dc_09360437d17f

How to cite

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or… — Europe PMC PMID:41077611 — Europe PMC (en), https://europepmc.org/article/MED/41077611 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_09360437d17f (Metraipolis archive dc_09360437d17f, sha256 223b9878a15f36640f6b443675bb3214c029693390e2237872ca7c2e306dbdee)
BibTeX
@misc{dc09360437d17f,
  title = {First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or… — Europe PMC PMID:41077611},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41077611},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_09360437d17f; sha256 223b9878a15f36640f6b443675bb3214c029693390e2237872ca7c2e306dbdee},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41077611. Agents can read the archived copy with the MCP tool read_document.